104 related articles for article (PubMed ID: 17969403)
1. [Effect of systemic chemotherapy on clinical status and biological and immunologic markers in patients with breast cancer].
Orlova RV; Chernetsova LF; Matveeva ON
Vopr Onkol; 2007; 53(4):414-8. PubMed ID: 17969403
[TBL] [Abstract][Full Text] [Related]
2. [Individualization of polychemotherapy for stage III breast cancer based on immunologic status].
Sabala PI
Vopr Onkol; 1984; 30(11):44-8. PubMed ID: 6516259
[TBL] [Abstract][Full Text] [Related]
3. Influence of therapy on the antioxidant status in patients with melanoma.
Gadjeva V; Dimov A; Georgieva N
J Clin Pharm Ther; 2008 Apr; 33(2):179-85. PubMed ID: 18315784
[TBL] [Abstract][Full Text] [Related]
4. Investigations on cell-mediated immunity in patients with breast and ovarian carcinomas receiving a combination of chemotherapy and immunotherapy with thymopentin.
Mallmann P; Krebs D
Methods Find Exp Clin Pharmacol; 1990 Jun; 12(5):333-40. PubMed ID: 2232966
[TBL] [Abstract][Full Text] [Related]
5. [Antioxidant status of patients with primary colorectal cancer and liver metastases of colorectal cancer].
Czeczot H; Skrzycki M; Podsiad M; Gawryszewska E; Nyckowski P; Porembska Z
Pol Merkur Lekarski; 2005 Jan; 18(103):58-61. PubMed ID: 15859549
[TBL] [Abstract][Full Text] [Related]
6. Lipid peroxidation and antioxidant status in patients with breast cancer.
Rajneesh CP; Manimaran A; Sasikala KR; Adaikappan P
Singapore Med J; 2008 Aug; 49(8):640-3. PubMed ID: 18756349
[TBL] [Abstract][Full Text] [Related]
7. [Comparative evaluation of the lymphocyte blast-transformation reaction induced by various mitogens in the polychemotherapy of patients with breast cancer].
Gnatyshak AI; Sabala PI
Eksp Onkol; 1984; 6(1):61-3. PubMed ID: 6499735
[TBL] [Abstract][Full Text] [Related]
8. Influence of Ukrain on patients with surgically treated breast cancer. Part III. The immune system.
Fomin KA; Uglyanica KN; Nefyodov LI; Djurd TI; Nowicky JW; Brzosko WJ; Jankowski A
Drugs Exp Clin Res; 1996; 22(3-5):143-5. PubMed ID: 8899318
[TBL] [Abstract][Full Text] [Related]
9. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy.
Li X; Lewis MT; Huang J; Gutierrez C; Osborne CK; Wu MF; Hilsenbeck SG; Pavlick A; Zhang X; Chamness GC; Wong H; Rosen J; Chang JC
J Natl Cancer Inst; 2008 May; 100(9):672-9. PubMed ID: 18445819
[TBL] [Abstract][Full Text] [Related]
10. [Assessment of the immunological status of chondrosarcoma patients].
Korolev VI; Kamenets LIa
Eksp Onkol; 1986; 8(1):63-5. PubMed ID: 3948760
[TBL] [Abstract][Full Text] [Related]
11. Increased oxidative/nitrosative stress and decreased antioxidant enzyme activities in prostate cancer.
Arsova-Sarafinovska Z; Eken A; Matevska N; Erdem O; Sayal A; Savaser A; Banev S; Petrovski D; Dzikova S; Georgiev V; Sikole A; Ozgök Y; Suturkova L; Dimovski AJ; Aydin A
Clin Biochem; 2009 Aug; 42(12):1228-35. PubMed ID: 19465015
[TBL] [Abstract][Full Text] [Related]
12. Antioxidant status and lipid peroxidation in the blood of breast cancer patients of different ages.
Kasapović J; Pejić S; Todorović A; Stojiljković V; Pajović SB
Cell Biochem Funct; 2008 Aug; 26(6):723-30. PubMed ID: 18636415
[TBL] [Abstract][Full Text] [Related]
13. Common adjuvant breast cancer therapies do not inhibit cancer vaccine induced T cell immunity.
Coveler AL; Goodell V; Webster DJ; Salazar LG; Fintak PA; Childs JS; Higgins DM; Disis ML
Breast Cancer Res Treat; 2009 Jan; 113(1):95-100. PubMed ID: 18236151
[TBL] [Abstract][Full Text] [Related]
14. Loss of retinoblastoma tumor suppressor protein makes human breast cancer cells more sensitive to antimetabolite exposure.
Derenzini M; Donati G; Mazzini G; Montanaro L; Vici M; Ceccarelli C; Santini D; Taffurelli M; Treré D
Clin Cancer Res; 2008 Apr; 14(7):2199-209. PubMed ID: 18381962
[TBL] [Abstract][Full Text] [Related]
15. [Comparison of blood-serum p53 concentrations in patients with advanced breast tumors before and after chemotherapy].
Mil' EM; Korman DB; Myshliakova OV; Mikaélian SG
Vopr Onkol; 2006; 52(2):159-63. PubMed ID: 17195640
[TBL] [Abstract][Full Text] [Related]
16. [Hemosorption as a method of unblocking immunotherapy].
Bilynskiĭ BT; Ts'olko RN; Shnittser IuM
Vopr Onkol; 1986; 32(6):87-92. PubMed ID: 3727488
[TBL] [Abstract][Full Text] [Related]
17. [A case of stage IV breast cancer in which a long-term no change state (NC) was attained by a combination of S-1 and TAM following AC-T as a primary systemic therapy (PST)].
Iizuka M; Sengoku N; Nakakuma T; Yoshimura N; Hayashi K; Enomoto T; Kuranami M; Watanabe M
Gan To Kagaku Ryoho; 2008 Nov; 35(12):2228-30. PubMed ID: 19106579
[TBL] [Abstract][Full Text] [Related]
18. [Parameters of cellular immunity in lung cancer patients with different types of adaptation reactions during polychemotherapy].
Stakheeva MN; Dizer IA; Smol'ianinov ES; Goldberg VE; Novitskiĭ EV; Sherstoboev EIu; Khlusova MIu
Vopr Onkol; 1998; 44(2):164-6. PubMed ID: 9615819
[TBL] [Abstract][Full Text] [Related]
19. Biological markers as predictive factors of response to neoadjuvant taxanes and anthracycline chemotherapy in breast carcinoma.
Zhou B; Yang DQ; Xie F
Chin Med J (Engl); 2008 Mar; 121(5):387-91. PubMed ID: 18364105
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
